Rontalizumab

From WikiMD.org
Jump to navigation Jump to search

Rontalizumab

Rontalizumab (pronunciation: ron-ta-li-zu-mab) is a monoclonal antibody designed for the treatment of autoimmune diseases. It was developed by Genentech, a member of the Roche Group.

Etymology

The name "Rontalizumab" is derived from the standard nomenclature for monoclonal antibodies. The suffix "-mab" indicates it is a monoclonal antibody, while the prefix "Rontaliz-" is a unique identifier.

Mechanism of Action

Rontalizumab works by inhibiting the interferon alpha (IFN-α), a protein that plays a crucial role in the immune response. By blocking IFN-α, Rontalizumab can help reduce the symptoms of autoimmune diseases.

Clinical Trials

Rontalizumab has undergone several clinical trials for conditions such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). However, the results have been mixed, and the drug is not currently approved for use in any country.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski